U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H11F3N2O2
Molecular Weight 296.2445
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUNIXIN

SMILES

CC1=C(NC2=C(C=CC=N2)C(O)=O)C=CC=C1C(F)(F)F

InChI

InChIKey=NOOCSNJCXJYGPE-UHFFFAOYSA-N
InChI=1S/C14H11F3N2O2/c1-8-10(14(15,16)17)5-2-6-11(8)19-12-9(13(20)21)4-3-7-18-12/h2-7H,1H3,(H,18,19)(H,20,21)

HIDE SMILES / InChI
Flunixin meglumine is a potent, non-narcotic, non-steroidal, analgesic agent with anti-inflammatory and anti-pyretic activity was approved to use in horses, cattle and pigs. In horses it is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders. It is also recommended for the alleviation of visceral pain associated with colic. In the cattle: it is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. It is also indicated for the control of inflammation in endotoxemia. Flunixin persists in inflammatory tissues and is associated with anti-inflammatory properties which extend well beyond the period associated with detectable plasma drug concentration. Flunixin meglumine is classified as a carboxylic acid. Its mechanism of action is believed to be primarily via the inhibition of cyclooxygenase (COX) enzymes. This inhibition results in decreased formation of cyclooxygenase-derived eicosanoids involved in the pathophysiology of inflammation, such as thromboxanes and prostaglandins.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: O19183
Gene ID: 791253.0
Gene Symbol: PTGS2
Target Organism: Equus caballus (Horse)
Conditions
PubMed

PubMed

TitleDatePubMed
Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.
2003 Sep
Patents

Sample Use Guides

in veterinary: Horse: The recommended dose for musculoskeletal disorders is 0.5 mg per pound (1 mL/100 lbs) of body weight once daily. Treatment may be given by intravenous or intramuscular injection and repeated for up to five days. Studies show onset of activity is within 2 hours. Peak response occurs between 12 and 16 hours and duration of activity is 24-36 hours. Intravenous administration is recommended for prompt relief. Clinical studies show pain is alleviated in less than 15 minutes in many cases. Treatment may be repeated when signs of colic recur. During clinical studies approximately 10% of the horses required one or two additional treatments. The cause of the colic should be determined and treated with concomitant therapy. Cattle: The recommended dose for control of pyrexia associated with bovine respiratory disease and endotoxemia and control of inflammation in endotoxemia is 1.1 to 2.2 mg/kg (0.5 to 1mg/lb; 1 to 2 mL per 100 lbs) of body weight given by slow intravenous administration either once a day as a single dose or divided into two doses administered at 12 hour intervals for up to 3 days. The total daily dose should not exceed 2.2 mg/kg (1.0 mg/lb) of body weight. Avoid rapid intravenous administration of the drug. The recommended dose for acute bovine mastitis is 2.2 mg/kg (1.0 mg/lb: 2 mL per 100 lbs) of body weight given once by intravenous administration.
Route of Administration: Other
It was investigated the effect of flunixin meglumine (FM), prostaglandin F2 alpha (PGF2α) and FM combined with PGF2α supplementation in culture medium (IVC-II) on the development and quality of in vitro produced bovine embryos. The development rate of embryos was significantly higher in the FM group (33.3%) than in control (24.3%), PGF2 α (23.9%) and FM + PGF2 α groups (24.5%). The percentage of hatched blastocysts was also higher (p < 0.05) in the FM group (41.2%) than in the control (27.8%) and PGF2 α groups (19.8%). While, there was no significant difference in total cell number in all experimental groups, the number of apoptotic cells was significantly higher in the PGF2 α group (8.2 ± 6.6) than in the control (4.7 ± 3.2), FM (4.7 ± 2.5) and FM + PGF2 α (4.9 ± 3.4) groups. It was concluded, that addition of FM in vitro culture significantly improved embryo development as well as alleviated the negative impact of PGF2 α.
Name Type Language
FLUNIXIN
INN   MI   USAN  
USAN   INN  
Official Name English
SCH-14714
Code English
FLUNIXIN [MI]
Common Name English
flunixin [INN]
Common Name English
SCH 14714
Code English
2-(.ALPHA.(SUP 3),.ALPHA.(SUP 3),.ALPHA.(SUP 3)-TRIFLUORO-2,3-XYLIDINO)NICOTINIC ACID.
Common Name English
3-PYRIDINECARBOXYLIC ACID, 2-((2-METHYL-3-(TRIFLUOROMETHYL)PHENYL)AMINO)-
Common Name English
FLUNIXIN [USAN]
Common Name English
FLUNIXIN [GREEN BOOK]
Common Name English
Classification Tree Code System Code
WHO-VATC QM01AG90
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
CFR 21 CFR 522.1664
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
CFR 21 CFR 520.970
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
CFR 21 CFR 556.286
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
NCI_THESAURUS C257
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
CFR 21 CFR 522.970
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
CFR 21 CFR 522.956
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
Code System Code Type Description
DRUG BANK
DB11518
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY
EVMPD
SUB07711MIG
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY
FDA UNII
356IB1O400
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY
PUBCHEM
38081
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY
MERCK INDEX
m5448
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY Merck Index
RXCUI
25121
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C65721
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY
MESH
C014557
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY
ChEMBL
CHEMBL1617398
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY
DAILYMED
356IB1O400
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY
CHEBI
76138
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY
EPA CompTox
DTXSID4048565
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY
CAS
38677-85-9
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY
WIKIPEDIA
FLUNIXIN
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY
SMS_ID
100000080712
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY
INN
3533
Created by admin on Fri Dec 15 15:10:34 GMT 2023 , Edited by admin on Fri Dec 15 15:10:34 GMT 2023
PRIMARY